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Abstract
Background: Serine/arginine-rich splicing factors (SRSFs) and HNRNPA1 have oncogenic properties. However, their
proteomic expressions and practical priority in gastric cancer (GC) and colorectal cancer (CRC) are mostly unknown.
To apply SFs in clinics, effective marker selection and characterization of properties in the target organ are essential.
Methods: We concurrently analyzed SRSF1, 3, and 5–7, and HNRNPA1, together with the conventional tumor
marker carcinoembryonic antigen (CEA), in stomach and colorectal tissue samples (n = 420) using semiquantitative
immunoblot, subcellular fractionation, and quantitative real-time polymerase chain reaction methods.
Results: In the semiquantitative immunoblot analysis, HNRNPA1 and SRSF7 levels were significantly higher in GC
than in gastric normal mucosa, and SRSF7 levels were higher in intestinal-type compared with diffuse-type of
gastric adenocarcinoma. Of the SFs, only HNRNPA1 presented greater than 50 % upregulation (cancer/normal
mucosa > 2-fold) incidences and CEA-comparable, acceptable (>70 %) detection accuracy (74 %) for GC. All SF
protein levels were significantly higher in CRC than in colorectal normal mucosa, and HNRNPA1 levels were higher
in low-stage CRC compared with high-stage CRC. Among the SFs, HNRNPA1 and SRSF3 presented the two highest
upregulation incidences (88 % and 74 %, respectively) and detection accuracy (90 % and 84 %, respectively) for
CRC. The detection accuracy of HNRNPA1 was comparable to that of CEA in low (≤ II)-stage CRC but was inferior to
that of CEA in high (>II)-stage CRC. Extranuclear distributions of HNRNPA1 and SRSF6 (cytosol/microsome) differed
from those of other SRSFs (membrane/organelle) in both cancers. In an analysis of the six SF mRNAs, all mRNAs
presented unacceptable detection accuracies (≤70 %) in both cancers, and all mRNAs except SRSF6 were
disproportionate to the corresponding protein levels in GC.
Conclusion: Our results provide a comprehensive insight into the six SF expression profiles in GC and indicate that,
among the SFs, HNRNPA1, but not HNRNPA1 mRNA, is the most effective, novel GC marker. Regardless of the good
to excellent detection accuracy of SRSF3 and HNRNPA1 in CRC, the SFs have lower practical priority than CEA,
especially for high-stage CRC detection.
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Background
Alternative splicing is a ubiquitous post-transcriptional
process that leads to proteomic diversity and the disrup-
tion of splicing regulatory networks is a critical compo-
nent of carcinogenesis.
The serine/arginine (SR) protein family is an import-
ant class of splicing regulators and its members, includ-
ing SR splicing factor (SF) 1, SRSF3, and SRSF6, have
shown multiple proto-oncogenic properties and aberrant
expressions in various cancer cells [1–4]. SRSF1, 3, and
7 shuttle between nucleus and cytoplasm, and their sub-
cellular distribution is associated with various cellular
functions and reactive responses [5–7]. For instance, in
the nuclear compartment of cells, SFs promotes the spli-
cing process, while in the extranuclear compartment,
they regulate protein translation [5]. In this sense, SFs
are found in ribosomes, the translation machinery [5],
and are expected to colocalize with SF-binding transla-
tion regulatory proteins such as the target of rapamycin
complex 1 (TORC1), which locates in lysosomes or in
cytosol [6]. Additionally, specific cellular stresses or con-
ditions induce post-translational modifications of SFs
which associated with cytoplasmic localization and the
stability of SFs and/or inhibit general splicing process in
nucleus [5–8].
Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1)
is also a well-known splicing regulator with effects
antagonistic to SR proteins [9]. Upregulated expression
and aberrant cytoplasmic localization of HNRNPA1, as
determined by immunohistochemical staining, were noted
in colorectal cancer (CRC) [10]. Recently, HNRNPA1 has
emerged as a plausible biomarker of CRC [11].
However, in gastric cancer (GC), proteomic expres-
sions of these SFs are unclear and their diagnostic values
have not been determined. The comparative practical
priority among the SR proteins and conventional tumor
markers in GC and CRC is unknown. Moreover, it is un-
clear as to whether the expression patterns and practical
priority of these SFs differ between the cancers.
We aimed to: (1) identify the translational and tran-
scriptional profiles of five SRSFs (SRSF1, SRSF3, SRSF5,
SRSF6, and SRSF7) and HNRNPA1 in GC; and (2) com-
pare the detection accuracy (DA) among the SFs and the
currently used tumor marker carcinoembryonic antigen
(CEA) [12] and determine specific features in these pa-
rameters in GC and CRC.
Methods
Subjects and sample preparation
A total of 420 fresh stomach and colon biopsy samples
were obtained from 224 patients (Table 1) who had
undergone surgical resection.
All tumor samples and patients were defined and diag-
nosed, respectively, at the Department of Pathology and
Surgery, Wonkwang University Hospital. Each fresh bi-
opsy sample was aliquoted into two or four tubes. The
first sub-sample was stored frozen in liquid nitrogen
until immunoblot analysis; the second was immediately
fixed with formalin, paraffin embedded, then stored for
hematoxylin and eosin staining and immunohistochemi-
cal staining; the third was immediately homogenized for
subcellular fractionation; and for the fourth, RNA was
immediately extracted and the RNA was reverse tran-
scripted. The synthesized cDNA sample was stored fro-
zen at −75 °C until real-time polymerase chain reaction
(PCR) analysis. All paraffin-embedded tissue samples
were sectioned, stained with hematoxylin and eosin and
evaluated twice by two pathologists. All histological find-
ings were consistent with the diagnosis, and all were
concordant between the two pathologists. All sections of
cancer tissue included at least 30 % cancer cells, and
none showed light microscopically-detectable degener-
ation or necrosis. Aneuploidy status was determined
using routine clinical laboratory diagnostic methods
consisting of propidium iodide staining followed by flow
cytometric analysis. The SW1116 cell line (a CEA-
producing colon cancer cell line) was obtained from the
American Type Culture Collection and used between
passage 3 and 8 after they were obtained.
Immunoblot and semiquantitative analysis of SF proteins
and CEA
Tissue samples (40 mg) were homogenized in RIPA
buffer containing protease inhibitors using a Bullet
Blender homogenizer (Next Advance; Averill Park,
NY, USA), and whole-cell lysate was obtained by se-
quential centrifugations. Proteins (~30 μg) in the whole-
cell lysate were separated on 10 % sodium dodecyl
sulfate–polyacrylamide gels with SW1116 cell protein
(~30 μg). The proteins were transferred onto polyvinyli-
dene difluoride membranes. The membranes were
blocked with 5 % skim milk in Tris-buffered saline con-
taining 0.1 % Tween 20 (TBS-T), rinsed, and incubated
with the appropriate antibodies in TBS-T containing 3 %
skim milk. Excess primary antibody was then removed by
washing the membrane four times in TBS-T. The mem-
branes were then incubated with horseradish peroxidase-
conjugated secondary antibody (anti-rabbit or anti-
mouse). After three washes in TBS-T, bands were vi-
sualized using Clarity Western ECL Substrate (Biorad;
Hercules, CA, USA) on the FluorChem E System
(Protein Simple; Santa Clara, CA, USA). The following
primary antibodies were used in the immunoblot analysis
of whole- or fractionated cell lysates: anti-HNRNPA1
(dilution 1:2000; cat. sc-32301; Santa Cruz Biotechnology;
Santa Cruz, CA, USA); anti-SRSF1 (dilution 1:1000; cat.
324600; Invitrogen; Carlsbad, CA, USA); anti-SRSF3
(dilution 1:1000; cat. RN080PW; MBL; Nagoya, Japan);
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Table 1 Demographic characteristics of subjects and tumors
Stomach (n = 147) Colon and rectum (n = 273)
SFa (pa) SFa (pa)





Sample pairing, n (GC/NM) (CRC/adenoma/NM)
Doubletb 60 (60/60) 120 (113/7/120)
Tripletc – 8 (8/8/8)
Unpaired (singlet) 27 (0/27) 9 (2/0/7)
Subjects (n = 224), n 87 137
Age, mean (range), years 66 (40–86) NS-all SFs 69 (45–90) NS-all SFs
≥65 years, n (%) 32 (53) 87 (71)
Gender, male, n (%) 90 (61) NS-all SFs 193 (71) NS-all SFs
Type of cancer, n
AC 56 AC 120
Otherd 4 Othere 3
Location of AC, n (%) NS-all SFs NS-all SFs
Cardia 5 (9) Proximalf 29 (24)
Body 13 (23) Distalf 63 (53)
Antrum 38 (68) Rectum 28 (23)
Histologic feature of AC, n (%) Type SRSF7 (0.049) Differentiation HNRNPA1 (0.020)
Intestinal 44 (79) 7.0 (2.0–29.0) Well 37 (31) 7.0 (4.2–11.0)
Diffuseg 12 (21) 2.9 (1.9–4.8) Moderate 83 (69) 5.0 (2.1–8.0)
and poor
Tumor status of AC, n (%) NS-all SFs NS-all SFs
T1, T2 27 (48) – 19 (16) –
T3, T4 29 (52) – 101 (84) –
LN metastasis of AC, n (%) NS-all SFs HNRNPA1 (0.003)
N0 28 (50) – 62 (52) 7.0 (4.0–10.0)
N1, N2, N3 28 (50) – 58 (48) 4.3 (1.9–7.5)
TNM stageh of AC, n (%) NS-all SFs HNRNPA1 (0.003)
I, II 40 (71) – 62 (52) 7.0 (4.0–10.0)
III, IV 16 (29) – 58 (48) 4.3 (1.9–7.5)
Aneuploidy status of AC, n (%) NS-all SFs NS-all SFs
≤ 3 % 50 (91) – 72 (66) –
> 3 % 5 (9) – 37 (34) –
Abbreviations: AC adenocarcinoma, CRC colorectal cancer, CEA carcinoembryonic antigen, GC gastric cancer, IQR interquartile range, LN lymph node, NM normal
mucosa, NS-all SFs not significant (p >0.05) for all splicing factor proteins and their mRNAs; SF = splicing factor
aSF name, p values, and median relative band intensity were described only for SF proteins or mRNAs that had a p value less than 0.05 in the six SFs; p values
were acquired by Mann-Whitney U-test (between two groups) or Kruskal-Wallis test
bTwo samples (cancer with its adjacent NM or adenoma with its adjacent NM) acquired from the same patient
cThree samples (cancer, adenoma, and their adjacent NM) were acquired from the same patient
dGastrointestinal stromal tumor (n = 3) and neuroendocrine carcinoma (n = 1)
eLymphoma (n = 2) and malignant melanoma (n = 1)
fProximal colon indicates cecum, ascending colon, and transverse colon. Distal colon indicates splenic flexure, descending colon, sigmoid colon, and rectosigmoid junction
gFive cases of mixed type were included
hTNM stage was determined based on the 7th edition of AJCC/UICC TNM classification. Low- and high-stage indicate TNM stage I/II and III/IV, respectively
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anti-SRSF5, anti-SRSF6, anti-SRSF7 (dilution 1:1000; cat.
HPA 043484, HPA029005, HPA043850; Sigma-Aldrich;
St. Louis, MO, USA); anti-CEA (dilution 1:3000; cat. MS-
613-P; Thermo Fisher Scientific; Fremont, CA, USA);
anti-ACTB (dilution 1:5000; cat. MA5-15739; Invitrogen);
anti-poly (ADP-ribose) polymerase (PARP; dilution
1:1000; cat. sc-7150; Santa Cruz Biotechnology); anti-
histone H3 (dilution 1:1000; cat. 9715 s; Cell Signaling;
Beverly, MA, USA); and anti-prohibitin (dilution 1:1000;
cat. AB28172; Abcam; Cambridge, UK).
Then, the optical density of the region of the target
molecular weight (±20 %), as described by the respective
antibody manufacturers, was analyzed using ImageJ
(http://imagej.nih.gov/ij/). Relative protein levels of the
samples were determined after normalization to the β-
actin band and calibrated using bands from SW1116
cells (a value of 10 was assigned to the SW1116 cell) on
each membrane. As presented in previous reports
[13–15] and/or manufacturers’ instructions, SRSF1,
SRSF6, SRSF7, HNRNPA1, and CEA showed multiple
bands in each target molecular weight area. For the
five proteins, multiple bands in each target molecular
weight area were calculated and the sum of the dis-
tinct band/bands was then analyzed for the proteins.
Values of 0.2 (HNRNPA1 and CEA), 0.7 (SRSF1), 0.8
(SRSF3, SRSF5, and SRSF7) or 1.0 (SRSF6) were assigned
to the undetected bands of target regions based on band
density of SW1116 cell lysate.
Subcellular fractionation and immunoblot
Ten paired [normal mucosa (NM) and cancer] samples
(n = 20) were fractionated using a modification of the
method described previously [16–18]. Tissue samples
(70 mg) were homogenized in 800 μL of homogenization
buffer [0.25 M sucrose, 10 mM EDTA, 10 mM EGTA,
2 mM MgCl2, 20 mM Tris–HCl (pH 7.4) and protease
inhibitors]. The homogenized lysate was centrifuged at
1500 × g for 5 min at 4 °C, and the resulting pellet,
containing nuclei, and the supernatant (post-nuclear
supernatant) were separated. Subsequently, the pellet,
containing nuclei, was resuspended in nuclear extraction
buffer [2.5 % glycerol, 1 mM EDTA, 1 mM EGTA,
1.5 mM MgCl2, 0.42 M NaCl, and 20 mM HEPES
(pH 7.6)] for 1 h at 4 °C, centrifuged again at 20000 × g
for 30 min at 4 °C. The supernatant was then collected
and referred to as the nuclear extraction fraction. In par-
allel, the post-nuclear supernatant was centrifuged at
20000 × g for 30 min at 4 °C and the resulting super-
natant was saved as the cytosol/microsome fraction. The
pellet was resuspended in RIPA buffer for 10 min at 4 °C
followed by centrifugation at 1500 × g for 5 min at 4 °C,
and the resulting supernatant was collected and referred
to as the membrane/organelle fraction, including
intracellular membranes and some plasma membrane.
Immunoblot analysis was performed on these three
fractions (nuclear extract, membrane/organelle, and
cytosol/microsome) as described above.
The resultant three fractions differed in terms of the
total protein amounts (membrane/organelle < nuclear
extract < cytosol/microsome) for all tissue samples. In
addition, the subcellular fraction indicator proteins
(PARP, histone H3, and prohibitin) showed inter-
individual and intra-individual (cancer vs. NM) varia-
tions. Accordingly, to compare the relative SF expression
levels for the respective fractions, an equal amount of
total protein per lane was loaded.
Enzymatic immunohistochemical staining
Formalin-fixed, paraffin-embedded tissue was sectioned
and placed on slides. Sections were stained using the
Discovery XT automated immunohistochemistry (IHC)
stainer (Ventana Medical Systems; Tucson, AZ, USA)
and Ventana Chromo Map Kit (Ventana Medical
Systems) according to the manufacturer’s instructions.
The sections were deparaffinized using EZ prep solution;
the antigen was retrieved in cell a conditioning solution
(CC1; Ventana Medical Systems) under standard condi-
tions (100 °C, 60 min), and endogenous peroxidase was
inhibited by treatment with 3 % H2O2 for 4 min. Then,
the sections on slides were incubated with the primary
antibody that had been used in the immunoblot analysis
(dilution 1:300 for anti-HNRNPA1 and anti-CEA and di-
lution 1:100 for other antibodies) for 60 min at 37 °C,
and then with a secondary antibody (UltraMap anti-RB
HRP or UltraMap anti-MS HRP; Ventana Medical
Systems) for 28 min at 37 °C. The sections were incu-
bated in diamidobenzidine and H2O2 for 8 min at 37 °C
followed by counterstaining with hematoxylin and treat-
ment with bluing solution. On completion of staining,
sections were dehydrated in alcohol, cleared in xylene,
and mounted in synthetic resin.
mRNA quantification using quantitative real-time PCR
Total RNA from 40 mg of tissue sample was isolated
using 1 mL of TRIzol (Life technologies; Carlsbad, CA,
USA) in accordance with the manufacturer’s instructions.
RNA (500 ng) was reverse transcribed using ReverTra Ace
qPCR RT Kits (Toyobo; Osaka, Japan). Quantitative real-
time PCR was performed in a StepOnePlus Real-Time
PCR System (Applied Biosystems; Foster City, CA, USA)
using a SYBR Green Realtime PCR Master Mix (Toyobo)
in accordance with the manufacturer’s instructions. Each
assay was performed in triplicate, and results were
normalized to 18S rRNA levels. Relative mRNA level
was calculated using StepOne software v.2.2.2 and
calibrated to that of SW1116 cell sample (A value of
10 was assigned to the mRNA level of SW1116 cell)
in each batch test.
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All group values were non-normally distributed in the
Kolmogorov-Smirnov test (p < 0.05). Thus, the values
were compared using the Mann–Whitney U-test
(between two groups) or Kruskal-Wallis test (among
more than two groups). If values were significantly dif-
ferent in the Kruskal-Wallis test, Conover’s post-hoc
tests were performed. Ratios were compared using the
chi-square test for comparison of incidences between
GC and CRC. Spearman correlations were used to assess
relationships among the levels of SF proteins or CEA
and levels of SF mRNAs. The DAs of each SF for dis-
criminating between cancer and NM were obtained by
constructing receiver operating characteristic curves.
The cut-offs for defining cancer were determined by the
respective highest Youden indexes. The statistical differ-
ences between the DAs were determined using the
DeLong method (for same-sample-derived comparison)
or a comparison of the areas under independent receiver
operating characteristic curves (for two independent
sample-derived comparisons).
Data were analyzed with MedCalc version 12.7
(MedCalc Software, Mariakerke, Belgium) and StatsDirect
version 2.7.8 (StatsDirect Ltd, Cheshire, UK). A two-tailed
p value of less than 0.05 was considered statistically
significant.
Results
Relative protein levels of the SFs and CEA in GC and CRC
In a comparison of relative immunoblot band intensity
(Fig. 1a and b) of stomach samples, the median levels of
HNRNPA1 (2.2 vs. 0.5; 4.4-fold difference; p < 0.001),
SRSF7 (4.8 vs. 3.0; 1.6-fold difference; p = 0.006), and
CEA (2.6 vs. 0.6; 4.3-fold difference; p < 0.001) were
significantly higher in GC samples than in gastric NM
(GNM) samples (Fig. 1b). Other SF protein median
levels were not significantly (p > 0.05) different between
GC and GNM samples.
In immunoblot analyses of CR samples (Fig. 1a and b),
the median levels of all six SFs and CEA were significantly
higher in CRC than in CRNM. Also, the median levels of
all SFs except SRSF1 were significantly higher in CR-
adenoma than in CRNM. HNRNPA1 and SRSF3 median
levels in CRC were most markedly higher than in CRNM
samples among the SFs. Median levels of the six SFs were
not lower or even higher in CR-adenoma samples com-
pared with CRC samples, but the median level of CEA
was lower in CR-adenoma than in CRC.
When GC and CRC were compared (Fig. 1b), median
levels of all SFs except SRSF1 were significantly higher
in CRC than in GC samples.
Association between the clinicopathologic factors and SF
protein levels
In an association analysis between the clinicopathologic
factors and SF proteins (Table 1), none of the SF protein
levels were significantly different based on patient age,
gender, or cancer location in both cancers. Most GCs
and CRCs were adenocarcinomas; in gastric adenocarcin-
oma, the median level of SRSF7 (7.0 vs. 2.9; p = 0.049) was
significantly higher in intestinal-type than in diffuse-type.
In CR-adenocarcinoma, the median level of HNRNPA1
was significantly higher in well-differentiated type (7.0 vs.
5.0; p = 0.020), no lymph node metastasis (7.0 vs. 4.3;
p = 0.003), or low (≤II)-stage (7.0 vs. 4.3; p = 0.003)
groups than in the other groups. Median levels of
other SF proteins, except HNRNPA1 and SRSF7, were
not significantly different based on tumor status, lymph
node metastasis, TNM stage, or aneuploidy status in both
gastric and CR adenocarcinoma.
Comparison of upregulation incidences of the SF and CEA
proteins in GC and CRC
In paired sample (cancer/NM from each same patient)
comparison (Table 2) of stomach samples, only HNRNPA1
showed >50 % upregulation (cancer/NM >2) incidence
(UI), followed by the other UIs in the order of HNRNPA1
(52 %), SRSF7 (42 %), and other SF proteins (22 %–33 %).
In CRC, all SFs except SRSF1 and SRSF5 showed UIs
of >50 % in the order of HNRNPA1 (88 %), SRSF3
(74 %), and other SFs (31 %–57 %). When UIs in GC and
CRC were compared, the UIs of all SFs were lower
(SRSF3, HNRNPA1, and SRSF6) or tended to be lower in
GC than in CRC; the differences between GC and CRC
were greatest for SRSF3 (40 %; p < 0.001), followed by
HNRNPA1 (36 %; p < 0.001), SRSF6 (24 %; p = 0.004), and
the other SFs. The UIs of CEA were >50 % in both can-
cers; it was also lower in GC (53 %) compared with CRC
(92 %), and the results were similar to HNRNPA1 values.
Comparison of DAs of the SF and CEA proteins in GC
and CRC
In the DA analysis (Table 2) for GC, only DA-
HNRNPA1 (74 %) was acceptable (>70 %), while the
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other SFs presented poor (≤70 %) DAs. The DAs of all
SFs were not significantly different between low- and
high-stage gastric adenocarcinoma. In CRC, all SFs ex-
cept SRSF1 and SRSF5 presented acceptable DAs in the
order of HNRNPA1 (90 %), SRSF3 (84 %), and the other
SFs (62–76 %). When the DAs for GC and CRC were
compared, the DAs of all SFs were lower (SRSF3,
HNRNPA1, and SRSF6) or tended to be lower in GC
than in CRC; the differences between GC and CRC were
greatest for SRSF3 (32 %; p < 0.001), followed by
HNRNPA1 (17 %; p < 0.001), SRSF6 (14 %; p = 0.006),
and the other SFs. The DAs of all SFs were not sig-
nificantly different based on the stage of CR-
adenocarcinoma, and the greatest difference between
GC and CRC being in SRSF3 was consistently ob-
served regardless of the stage. In the comparison with
CEA (Table 2), DA-HNRNPA1 was not different from
DA-CEA in both low- and high-stage gastric adeno-
carcinoma, whereas in CRC, DA-HNRNPA1 was not
different from DA-CEA in low-stage CR-adenocarcinoma,
but it was significantly lower than DA-CEA in high-stage
CR-adenocarcinoma.
Fig. 1 Proteomic expression of six SFs and CEA. a Representative semiquantitative immunoblot analysis of gastric and colorectal (CR) cancer (C)
and their adjacent normal mucosa (NM) tissue samples. β-actin (ACTB) was used as a loading control. SW1116 cell lysate was loaded as a
semiquantitative calibrator. For each SF and CEA, distinct bands in the following target molecular weights were analyzed: 29–39 kDa
(HNRNPA1), 27–33 kDa (SRSF1), 20 kDa (SRSF3), 36–40 kDa (SRSF6), 33–15 kDa (SRSF7), and 180–220 kDa (CEA). b Relative quantitation of SF
proteins and CEA in immunoblot analysis for gastric normal mucosa (GNM), gastric cancer (GC), colorectal NM (CRNM), CR cancer (CRC) and
CR-adenoma. Each bar indicates the median and the green horizontal lines indicate the interquartile ranges. The color (compared group)
matched small blocks above each median bar indicate the p value < 0.05 (by Kruskal-Wallis test followed by Conover’s post-hoc tests). c Representative
subcellular distribution analysis using biochemical fractionation and immunoblot method. Whole cell (wc); nuclear extract (nu); cytosol/microsome
(cyt); and membrane/organelle (me/og) fractions were loaded. The nuclear extract fraction was identified with poly (ADP-ribose) polymerase (PARP)
and histone H3 (H3) and membrane/organelle fraction was identified with prohibitin. Respective subcellular fractions were normalized using the total
protein quantity/ACTB. The actual experiment involved 10 paired samples (n = 20; 5 GC/GNM pairs and 5 CRC/CRNM pairs). d Representative
immunohistochemical staining analysis. The actual experiment involved 10 paired samples (n = 20; 5 GC/GNM pairs and 5 CRC/CRNM pairs)
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Subcellular distribution of SF proteins in GC and CRC
Previously, several studies showed SF distribution using
enzymatic IHC [7].
Generally, this method provides information about
both cellular morphology and tissue structural changes,
but it is limited when used for a clear discrimination of
Table 2 Comparison of upregulation incidences and detection accuracies of SFs and CEA in GC and CRC
Protein mRNA
Stomach Colon and rectum GC vs. CRC,
% difference (pb)
Stomach Colon and rectum GC vs. CRC,
% difference (pb)
UIa in paired samples; upregulated pair,
n/total pair, n (%)
HNRNPA1 or HNRNPA1 31/60 (52) 106/121 (88) 36 (< 0.001) 20/45 (44) 55/96 (57) 13 (0.214)
SRSF1 or SRSF1 13/60 (22) 38/121 (31) 10 (0.232) 17/45 (38) 37/96 (39) 1 (0.921)
SRSF3 or SRSF3 20/60 (33) 89/121 (74) 40 (< 0.001) 20/45 (44) 46/96 (48) 3 (0.838)
SRSF5 or SRSF5 15/60 (25) 48/121 (40) 15 (0.074) 16/45 (36) 20/96 (21) −15 (0.097)
SRSF6 or SRSF6 17/60 (28) 63/121 (52) 24 (0.004) 16/45 (36) 46/96 (48) 12 (0.232)
SRSF7 or SRSF7 25/60 (42) 69/121 (57) 15 (0.115) 18/45 (40) 45/96 (47) 7 (0.559)
CEA 32/60 (53) 111/121 (92) 38 (< 0.001) – – –
Detection accuracy, AUC
Allc (Sensitivity%/Specificity%) n = 147 n = 258 n = 111 n = 202
low-stage ACd n = 127 n = 197 n = 95 n = 153
high-stage ACd n = 103 n = 193 n = 78 n = 152
HNRNPA1 or HNRNPA1 0.74 (72/71) 0.90e (85/86) 17 (< 0.001) 0.58e,f (69/50) 0.69e,f (54/78) 11 (0.117)
0.71 0.93 23 (< 0.001) 0.54e 0.71e,f 17 (0.030)
0.77 0.89e 11 (0.141) 0.64e 0.64e,f 0 (1.000)
SRSF1 or SRSF1 0.58e,f (95/23) 0.62e,f (42/82) 4 (0.487) 0.55e,f (49/65) 0.61e,f (88/35) 6 (0.399)
0.56e 0.66e,f 10 (0.147) 0.53e 0.62e,f 9 (0.252)
0.66e 0.58e,f −8 (0.314) 0.63e 0.58e,f −6 (0.552)
SRSF3 or SRSF3 0.53e,f (53/57) 0.84e,f (81/78) 32 (<0.001) 0.59e,f (71/52) 0.65e,f (75/51) 7 (0.322)
0.56e,f 0.84e,f 28 (< 0.001) 0.54e 0.68e,f 14 (0.069)
0.55e,f 0.84e 29 (< 0.001) 0.60e 0.62e,f 16 (0.866)
SRSF5 or SRSF5 0.51e,f (60/51) 0.62e,f (35/89) 11 (0.062) 0.52e,f (91/23) 0.52e,f (78/38) 0 (0.953)
0.53e,f 0.65e,f 12 (0.101) 0.54e 0.51e,f −3 (0.718)
0.62e 0.58e,f −3 (0.701) 0.53e,f 0.54e,f 1 (0.914)
SRSF6 or SRSF6 0.61e,f (38/89) 0.76e,f (51/96) 14 (0.006) 0.58e,f (56/62) 0.67e,f (60/68) 9 (0.192)
0.60e 0.78e,f 18 (0.004) 0.53e,f 0.68e,f 15 (0.062)
0.56e,f 0.74e,f 18 (0.032) 0.61e 0.65e,f 4 (0.699)
SRSF7 or SRSF7 0.63e (30/84) 0.74e,f (59/83) 11 (0.066) 0.54e,f (38/80) 0.65e,f (85/43) 11 (0.125)
0.61e 0.75e,f 15 (0.036) 0.53e 0.66e,f 12 (0.126)
0.71e 0.73e,f 3 (0.755) 0.70e 0.64e,f −6 (0.474)
CEA 0.76 (57/89) 0.96f (92/94) 20 (< 0.001) – – –
0.77g 0.97 20 (< 0.001) – – –
0.90g 0.99f 9 (0.037) – – –
Abbreviations: AC adenocarcinoma, AUC area under the curve, CEA carcinoembryonic antigen, CRC colorectal cancer, GC gastric cancer, NM normal mucosa,
UI upregulation incidence
aUIs in cancer were acquired using paired samples from the same patient (cancer/NM >2-fold)
bp value was acquired by chi-square test
cAUCs were acquired for all types of cancer (including non-AC), regardless of TNM stage
dAUCs were acquired for low-stage AC (TNM stage I/II AC) or for high-stage AC (TNM stage III/IV AC)
ep < 0.05: compared with the respective AUC of CEA; p values for the paired AUC were acquired by the DeLong test
fp < 0.05: compared with the respective AUC of HNRNPA1; p values for the paired AUC acquired by the DeLong test
gp < 0.05: AUC of low-stage AC vs. AUC of high-stage AC; p values were acquired by independent receiver operating characteristic curve comparison test
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organelles (the major location of translation regulatory
molecules) from cytosol. So far, no study has demon-
strated the SF subcellular distribution in primary cancer
cells using biochemical fractionation and immunoblot-
ting. Using the biochemical fractionation approach
(Fig. 1c), we were able to more precisely distinguish the
extranuclear fractions. HNRNPA1 and SRSF6 in both
cancers frequently (≥50 %) showed different distribution
patterns from those of the other SFs. When HNRNPA1
and SRSF6 were upregulated in whole cancer-cell ly-
sates, they were predominantly distributed in nuclear
and/or cytosol/microsome fractions; the upregulated
SFs in the cytosol/microsome fraction were detectable
in >50 % of upregulated cases in both cancers. Alter-
natively, when SRSF1, 3, 5, and 7 were upregulated in
whole cancer-cell lysates, they were predominantly
distributed in nuclear and/or membrane/organelle frac-
tions; the upregulated SFs in the membrane/organelle
fraction were detectable in >50 % of upregulated cases
in both cancers. There were no remarkable differences in
subcellular distributions between GC and CRC. With re-
gard to methodological principle and analytical points,
biochemical fractionation followed by immunoblotting
differed from IHC. The former was normalized using
equal amounts of total protein per lane, while IHC images
were analyzed directly. During the former method
process, the nuclear and extranuclear fractions were tran-
siently treated in a different buffer, which may affect the
affinity of the antibody, and a certain amount of the pro-
tein in the border zone of the different fractions was dis-
carded to prevent contamination of a adjacent fraction.
Regarding these concerns, we only were able crudely to
match the nuclear and extranuclear fraction quantities,
and were not able to precisely match the distribution of
four SF proteins (SRSF 1, 3, 5, and 7) in the membrane/
organelle fraction to the corresponding fraction of the
enzymatic IHC analysis (Fig. 1d). Nonetheless, the two
methods showed an approximate match with regard to
whole-cell SF protein intensities.
Relative mRNA levels of the SFs in GC and CRC
In the SF mRNA level analysis (Fig. 2a), none of the six
SF median levels significantly differed between GC and
GNM. In contrast, all SFs except SRSF5 were signifi-
cantly higher in CRC than in CRNM.
None of the SF mRNA median levels were signifi-
cantly different based on histological features, lymph
node metastasis, or TNM stage in gastric or CR-
adenocarcinoma (Table 1).
In paired sample comparisons of mRNA (Table 2), all
SF mRNAs showed <50 % UI in GC, and only
HNRNPA1 showed >50 % UI in CRC.
In DA analysis of mRNA (Table 2), including DA-
HNRNPA1 (69 %) for CRC, which was the highest SF
mRNA DA, all of the SF mRNAs showed poor DAs for
both cancers. The UIs and DAs of all of the SF mRNAs
were not significantly different between GC and CRC
(Table 2).
Correlation between the SF proteins and their respective
mRNA levels
In correlation analysis (Fig. 2b), all SF proteins were sig-
nificantly correlated with each other and all SF mRNAs
were correlated with each other in both stomach and CR
samples.
None of the SF protein levels, except SRSF6, were cor-
related with their respective mRNA levels in stomach
samples. Whereas in CR samples, levels of three SF pro-
teins (HNRNPA1, SRSF3, and SRSF6), which had rela-
tively high DAs, were correlated with their respective
mRNA levels.
Discussion
Our study demonstrated, for the first time, the following:
(1) HNRNPA1 is the most useful, CEA-comparable
marker for GC among the six SF proteins and their
mRNAs, and HNRNPA1 and SRSF7 have significantly
elevated levels in GC tissue compared with GNM;
(2) comparative diagnostic priority of HNRNPA1 for
CRC is dependent on stage (i.e., DA-HNRNPA1 for
CR-adenocarcinoma is comparable to that of CEA in
low-stage, but inferior to high-stage, CR-adenocarcinoma)
(3) unlike in GC, SRSF3 presents relatively high UI and
very good DA in CRC; and (4) extranuclear distribution
patterns of HNRNPA1 and SRSF6 (cytosol/microsome)
differ from those of the other SFs (membrane/organelle)
in both cancers.
Although strong evidence supports the role of several
SFs in tumorigenesis [1–4, 14] and suggests their poten-
tial as diagnostic markers of cancers [11, 19], to apply
the SFs in clinics, identification of their DAs and specific
characteristics in the target organ is essential. In this re-
gard, we concurrently compared the six SFs and found
that only the levels of SRSF7 and HNRNPA1 are statisti-
cally significantly higher in GC than in GNM. Currently,
no reports have shown, with statistical significance,
elevated levels of SRSF7 in any type of primary can-
cer or elevated levels of HNRNPA1 in primary GC
samples. Our results present robust evidence for the
relationship between two SF proteins and GC using a
statistically valid sample number. In addition, we
found significantly higher levels of six SF proteins in
CRC than in CRNM. Previously, a study reported
amplified SRSF6 expression in primary CRC [3], but
the data was limited to the gene level. It is difficult
to find any report that shows significantly elevated
levels of the five SRSF proteins in primary CRC. Here, we
provide new evidence of a positive relationship between
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the five SRSFs and CRC in terms of the protein levels
using primary CRC samples.
Even though most GC and CRC originate from gastro-
intestinal tract mucosa and consist of adenocarcinomas,
when the SF protein levels were compared between GC
and CRC, CRC generally tended to show higher levels
than GC. In addition, UI and DA analyses demonstrated
significant differences between GC and CRC for
HNRNPA1, SRSF3, and SRSF6, and the difference in
SRSF3 was most marked. Although it is difficult to pin-
point the exact reason for this, we postulated that it is
related to the previously known different etiologies and
pathogenetic factors of GC and CRC [20–22]. These dif-
ferent findings for GC and CRC also hold true for our
CEA levels in GC and CRC.
None of the SRSF 5–7 and HNRNPA1 proteins showed
significant relationships with unfavorable histopathologic
or aneuploidy status [23] in gastric adenocarcinoma or
CR-adenocarcinoma. Instead, SRSF7 in gastric adenocar-
cinoma was higher in intestinal-type, which has a higher
survival rate than diffuse-type [24], and HNRNPA1 levels
in CRC were higher in well-differentiated, without nodal
involvement, or low-stage groups. Furthermore, all SF
protein levels in CR-adenoma were either not different
from or even higher than those of CRC, which has a
poorer prognosis than adenoma. Collectively, the elevated
levels of all SFs, especially the two SF proteins, do not
seem to correlate with poor prognostic factors in either
cancer. For the association between HNRNPA1 and prog-
nostic factors of CRC, previous reports showed contra-
dictory findings. One presented a higher upregulation
incidence of HNRNPA1 in low-stage group than in
high-stage group [25], while another [11] presented a
lower survival rate in patients who had higher
HNRNPA1 levels in CRC tissue. Our HNRNPA1 re-
sult was in line with the former finding. As a concur-
rent comparison study of the diagnostic performance
levels of multiple SF proteins, our study was designed
in a cross-sectional view for selection of a diagnostic
marker rather than a longitudinal view for identifica-
tion of a prognostic/predictive marker, which gener-
ally requires a 3–5-year follow-up period. In this
respect, although we do not formally report inconclu-
sive results at this point, we believe that our results
are also in line with the former one, since in our pre-
liminary survival analysis for 0.6–2.5 years, patients
with higher HNRNPA1 levels tended to have longer
relapse-free intervals and overall survival times.
Fig. 2 Relative mRNA levels of six SFs (a) and correlation analysis among the SF proteins and mRNAs (b). a Each bar indicates the median, and
the green horizontal lines indicate the interquartile ranges for gastric normal mucosa (GNM), gastric cancer (GC), colorectal NM (CRNM), CR cancer
(CRC), and CR-adenoma. The color (compared group) matched small blocks above each median bar indicate the p value < 0.05 (by Kruskal-Wallis
test followed by Conover’s post-hoc tests). b R1, S1, S3, S5, S6, and S7 indicate HNRNPA1, SRSF1, SRSF3, SRSF5, SRSF6, and SRSF7, respectively. The
numbers in colored cells (p < 0.05) or uncolored cells (p > 0.05) indicate the correlation coefficient (r)
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Considering the UIs and DAs among the six SFs,
HNRNPA1 was the most effective marker for both can-
cers. Analytical results in many cancer databases, includ-
ing The Cancer Genome Atlas (TCGA) data [26, 27],
partly supported our findings. Specifically, the SF mRNA
median levels in the TCGA data (<1.9-fold) were only
marginally upregulated in both cancers as in our mRNA
results. In contrast, in this study, HNRNPA1 protein
levels presented remarkably elevated levels (>4.4-fold) in
both cancers. Together, not only the direct comparison
within our data (protein vs. mRNA) but also the indirect
comparison with the results of the cancer database
(marked fold change of HNRNPA1 in this study vs. mar-
ginal fold change of HNRNPA1 in the database), to a
degree, validated the relative excellence of HNRNPA1
compared with HNRNPA1. In addition, because the DA-
HNRNPA1 for GC and low-stage CRC were comparable
with the DA of CEA, one of the most commonly used
tumor markers for gastrointestinal cancers in clinical
practice, our results indicate that HNRNPA1 is applic-
able as a novel GC marker as well as an early CRC
marker. However, in high-stage CR-adenocarcinoma,
DA-HNRNPA1 was significantly inferior to DA-CEA.
For this, we assumed that HNRNPA1 production reaches
a plateau during the premalignant period in the course of
CRC progression. Alternatively, it may be due to microen-
vironmental factors or the instability of HNRNPA1 in a
large tumor mass. Among the SF proteins, SRSF7 in GC
and SRSF3 in CRC presented the second highest UI and
DA, respectively. However, these were less reliable detec-
tion markers of both cancers than CEA.
Although the aberrant cytoplasmic localization of
HNRNPA1 has already been observed in CRC tissue
[10], subcellular distribution analyses of SRSF3 and SRSF
5–7 in primary cancer cells are rare in the literature,
and no studies further describe the extranuclear frac-
tions (cytosol/microsome vs. membrane/organelle). We
employed a pilot approach using biochemical fraction-
ation and immunoblot assay for the SF distribution ana-
lysis in GC and CRC tissue. We detected aberrantly
upregulated proteins in the extranuclear fractions in both
types of cancer cells and noted that the major distribution
patterns of proteins in the extranuclear fractions differ
based on the SF type [HNRNPA1 and SRSF6 (cytosol/
microsome) vs. SRSF1, 3, 5, and 7 (membrane/organelle)]
rather than by cancer type (GC vs. CRC). The cytoplasmic
expression of SFs in our IHC analysis, especially promin-
ent in cancer samples, could be explained by two plausible
mechanisms: (1) tumor-specific translation control by SFs
and (2) tumorigenesis-prone or tumor-associated condi-
tions. Regarding the first mechanism, SFs interact with
translation regulators (tumor-promoting or -suppressing
factors), which are mainly found in cellular organelles
(membrane/organelle fraction) and cytosol (cytosol/
microsome fraction) [5, 6]. The second mechanism is
associated with the post-translational modification of SFs;
rapidly growing tumor cell-related or tumorigenesis-prone
stress/status (e.g., metaphase, hypoxia or ultraviolet
light) promotes the phosphorylation-related extranuclear
localization and/or induction of SF proteins [5, 7, 8].
Because HNRNPA1 and SRSFs have a well-known an-
tagonistic relationship [9], we expected an inverse cor-
relation between HNRNPA1 and SRSF proteins, but all
of the SF proteins showed positive correlations with each
other. All of the SF mRNAs also showed positive corre-
lations with each other in GC or in CRC. This may be
due to collapse of the normal homeostatic relationship
among the SFs in cancer cells and/or serial escalation
within the SF proteins or within the SF mRNAs. Mean-
while, five SF proteins in GC and three SF proteins in
CRC showed expression levels disproportional to those
of their respective mRNAs. This could be explained by
the specific kinetics of each SF or various post-
transcriptional modifications [28–30] that affect the SF
protein production rate or stability.
The major purpose of this study was to select an ef-
fective marker for GC. Through the comparison of pro-
teins and mRNAs, aside from selection of a specific SF,
our results indicate that the HNRNPA1 protein itself,
rather than its mRNA, is the most reliable tool for GC
detection among the SFs tested here.
Conclusions
Apart from indicating that among the six SFs,
HNRNPA1, but not HNRNPA1 mRNA, is the most clin-
ically applicable marker for GC, our results offer new
insight into the expression profiles and diagnostic effica-
cies of the six SFs in GC that is required for their future
practical implementations. Despite the frequent upregu-
lation and very good to excellent detection accuracy of
SRSF3 and HNRNPA1 in CRC, we still recommend the
use of CEA, rather than the SFs, especially for high-
stage CRC detection.
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